Showing posts with label Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma. Show all posts
Showing posts with label Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma. Show all posts
Friday, April 9, 2021

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

›
In continuation of my update on  Tivozanib AVEO Oncology (Nasdaq: AVEO)   announced  the U.S. Food and Drug Administration (FDA)   approval ...